Logo

SILO

Silo Pharma, Inc.

SILO

Silo Pharma, Inc. • NASDAQ
$0.47 ▲ 3.33% (+0.01)
Market Cap $3.70 M
52w High $3.37
52w Low $0.36
Dividend Yield 0%
P/E -0.51
Volume 151
Outstanding Shares 7.96M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $18.025K $918.734K ▼ $-1.11M ▲ -6.161K% ▲ $-0.12 ▲ $-1.107M ▲
Q2-2025 $18.025K ▼ $1.265M ▲ $-1.204M ▼ -6.681K% ▼ $-0.19 ▲ $-1.2M ▼
Q1-2025 $18.026K $1.111M ▼ $-1.031M ▲ -5.722K% ▲ $-0.23 ▲ $-1.026M ▲
Q4-2024 $18.026K ▲ $1.495M ▲ $-1.731M ▼ -9.601K% ▼ $-0.39 ▼ $-1.791M ▼
Q3-2024 $18.025K $1.027M $-928.814K -5.153K% $-0.22 $-924.641K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $5.938M ▼ $6.385M ▼ $1.376M ▼ $5.009M ▲
Q2-2025 $6.26M ▲ $6.653M ▲ $1.735M ▼ $4.917M ▲
Q1-2025 $5.451M ▼ $5.9M ▼ $1.889M ▼ $4.011M ▼
Q4-2024 $7.081M ▼ $7.412M ▼ $2.378M ▲ $5.034M ▼
Q3-2024 $8.015M $8.567M $1.784M $6.782M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.11M ▼ $-955.493K ▲ $-95.474K ▼ $634.922K ▼ $-416.045K ▼ $-955.49K ▲
Q2-2025 $1.031M ▲ $-1.285M ▲ $388.102K ▼ $2.094M ▲ $1.197M ▲ $-1.285M ▲
Q1-2025 $-1.031M ▲ $-1.64M ▼ $871.381K ▲ $0 $-768.919K ▲ $-1.64M ▼
Q4-2024 $-1.731M ▼ $-917.432K ▲ $-37.659K ▲ $0 ▼ $-955.091K ▼ $-917.432K ▲
Q3-2024 $-928.814K $-1.347M $-40.432K $1.742M $354.59K $-1.347M

Five-Year Company Overview

Income Statement

Income Statement Silo Pharma looks very much like an early-stage biotech from an income-statement perspective: there is effectively no product revenue yet and the business is being run as a research platform. Reported earnings per share jump around from year to year, but that mainly reflects accounting noise on a very small base rather than a shift toward profitability. Economically, the picture is simple: ongoing research and corporate costs with no commercial income so far, which means the company is likely operating at a loss while it develops its pipeline.

Balance Sheet

Balance Sheet The balance sheet appears extremely small, with only modest assets, minimal cash reported in recent periods, and no financial debt. Equity is positive but tiny, which suggests a company that has historically relied on small capital raises and still sits in a very lean, development-only phase. The absence of traditional debt is a plus for financial flexibility, but the low cash position and small asset base mean the business is likely sensitive to future funding conditions and market sentiment. The reported figures look rounded and sparse, so there is some uncertainty about the exact strength of the balance sheet, but the general picture is “lightly capitalized and early-stage.”

Cash Flow

Cash Flow Cash flow data are essentially flat in the disclosures, which usually means there are no meaningful inflows from operations and that any cash usage is modest in absolute dollars but still material relative to the company’s size. In practice, a company like this typically spends cash on preclinical work, collaborations, and overhead, funded by past or future equity raises rather than by internal cash generation. The diversification into cryptocurrencies adds an extra layer of volatility to the cash and treasury profile: it could help if prices rise, but it also exposes the company to swings in non-core assets that do not directly advance the drug pipeline.

Competitive Edge

Competitive Edge Competitively, Silo is trying to distinguish itself not by sheer scale but by focusing on niche, high-need areas and novel delivery technologies. Its emphasis on intranasal formulations and implantable delivery systems in PTSD, chronic pain, Alzheimer’s, and multiple sclerosis sets it apart from many peers that use more traditional oral or intravenous routes. Exclusive collaborations with universities and a strategy built around leveraging existing safety data through a streamlined regulatory path give it some structural advantages and intellectual property protection. At the same time, it operates in crowded, high-profile therapeutic areas where much larger and better-funded companies are also active, and where regulators and clinicians will demand very strong evidence before adoption, so its competitive position is promising but still unproven.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Silo’s story. The pipeline covers several experimental programs: an intranasal PTSD treatment aiming for rapid brain delivery, a slow-release ketamine implant targeting chronic pain without heavy psychoactive effects, an intranasal combination approach for Alzheimer’s, and a targeted peptide platform for multiple sclerosis that aims to home in on inflamed nervous-system tissue. Most of this work is still preclinical, meaning many scientific, regulatory, and commercial hurdles lie ahead. The use of the faster 505(b)(2) pathway where possible, plus collaborations with academic centers and specialist contract research partners, helps stretch limited R&D resources. A newer joint venture into obesity and metabolic disease hints at a willingness to pivot into large commercial markets, but it also adds scope and complexity to an already ambitious research agenda.

Summary

Overall, Silo Pharma is an early-stage biotechnology company with an innovation-heavy story and a very light financial footprint. The lack of revenue, dependence on external funding, and small balance sheet highlight typical risks of developmental biotechs: scientific uncertainty, regulatory hurdles, and the need to raise capital over time. On the other hand, the company’s focus on differentiated delivery technologies, strong academic partnerships, and use of a potentially faster regulatory route provide some structural advantages if its science holds up. Future value will largely depend on whether it can advance key programs like the PTSD and pain candidates into human trials, generate convincing data, and secure the funding needed to sustain that journey, all while managing the added volatility from non-core crypto investments and expansion into new therapeutic areas.

NEWS

November 17, 2025 · 8:05 AM UTC

Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD

Read more

October 29, 2025 · 8:25 AM UTC

Silo Pharma Selects Alphaledger's T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain

Read more

October 23, 2025 · 8:45 AM UTC

Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program

Read more

October 8, 2025 · 8:45 AM UTC

Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth

Read more

October 6, 2025 · 8:10 AM UTC

Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)

Read more